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*Streptococcus thermophilus* is a low-GC Gram-positive bacterium widely used by the dairy industry to obtain high-quality fermented products, such as yogurt and cheeses ([@B1]). As such, it is a rare nonpathogenic streptococcal species ([@B2]). Another distinctive feature of *S. thermophilus* is its production of lactic acid from only a few sugars, including glucose, lactose, and sucrose ([@B3]). Selecting a suitable industrial *S. thermophilus* strain is a long process, encouraging extensive use and thorough characterization of the available strains ([@B4]).

*S. thermophilus* SMQ-301 is an industrial strain used to make cheese that is also sensitive to several virulent phages, including the reference phage DT1 ([@B5]). Phage infection of bacterial cultures is still the main risk factor for slowed milk fermentation, and the dairy industry relies on various strategies to control this phenomenon ([@B4]). *S. thermophilus* SMQ-301 has been used in several studies on phage biology ([@B5][@B6][@B10]), clustered regularly interspaced short palindromic repeat (CRISPR)-Cas systems ([@B11][@B12][@B13]), and sugar metabolism ([@B3], [@B14], [@B15]). It has a similar pulsed-field gel electrophoresis restriction profile (data not shown) to that of *S. thermophilus* LMD-9 (1,856,368 bp, 39.1% G+C content, 1,834 genes, two plasmids; GenBank accession no. NC_008532), which is also sensitive to DT1 ([@B10]).

The genome of *S. thermophilus* SMQ-301 was sequenced using MiSeq (Illumina) and PacBio (Pacific Biosciences) platforms. DNA extraction, library preparation, and assembly were performed as described previously ([@B16]). Briefly, DNA was purified using Genomic-tip 20/G columns, according to the manufacturer's instructions. The genome was assembled into a single contig with the PacBio reads, according to the manufacturer's instructions, and base calling accuracy was verified and corrected using Illumina reads aligned with BLAT ([@B17]) to the PacBio assembly. The Illumina and PacBio data were highly concordant, with the exception of 27 loci that were corrected with the Illumina reads. The genome of 1,861,792 bp has a G+C content of 39.1%. SMQ-301 contains no plasmids. The RAST annotation server ([@B18]) was used to annotate the genome, which encodes 2,037 proteins, 67 tRNAs, and 18 rRNAs.

We identified three CRISPR-Cas loci in the genome of *S. thermophilus* SMQ-301. According to the classification of CRISPR-Cas systems ([@B19]), two of the loci are type II-A systems (CRISPR 1 and CRISPR 3), while the CRISPR-Cas 2 locus is a type III-A system. Moreover, SMQ-301 has 16 spacers in CRISPR 1, 3 spacers in CRISPR 2, and 15 spacers in CRISPR 3. The last 10 spacers (3′) of CRISPR 1 are identical to those of LMD-9, which also has 16 spacers. Both strains have the same 3 spacers in CRISPR 2, and they share 5 spacers in CRISPR 3, while LMD-9 has only 8 spacers in this locus. The genome of SMQ-301 also encodes two type-I restriction-modification systems. Although prophage genes were detected by Phast ([@B20]), no complete prophage is present.

No known toxins were identified in the coding sequence of *S. thermophilus* SMQ-301 by the Web server VirulenceFinder ([@B21]) or by comparing the protein sequences with the VFDB ([@B22]) and DBETH ([@B23]) toxin databases using BLASTp ([@B24]). Finally, no known antibiotic resistance genes were found in the genome of SMQ-301 in comparison with the antibiotic resistance database (ARG-ANNOT) ([@B25]).
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The complete annotated genome sequence of *S. thermophilus* SMQ-301 was deposited in GenBank under accession no. [CP011217](CP011217).
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